Grygoriy Tsenov

Dr. Grygoriy Tsenov


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2011 in Diabetologia
Verified
Journal Article
Closed access
PDF file
PFP. Flachs
P. Flachs
RRR. Rühl
R. Rühl
MHM. Hensler
M. Hensler
PJP. Janovska
P. Janovska
PZPetr Zouhar
Petr Zouhar
JKJan Kopecky
Jan Kopecky

29 July 2021 in Epilepsia
Verified
Journal Article
Open access
FMFrancesca Mengoni
Francesca Mengoni
VSValentina Salari
Valentina Salari
IKInna Kosenkova
Inna Kosenkova
GTGrygoriy Tsenov
Grygoriy Tsenov
Massimo DonadelliMassimo Donadelli
Massimo Donadelli
Paolo FabenePaolo Fabene
Paolo Fabene
A bulk of data suggest that the gut microbiota plays a role in a broad range of diseases, including those affecting the central nervous system. Recently, significant differences in the intestinal microbiota of patients with epilepsy, compared to healthy volunteers, have been reported in an observational study. However, an active role of the intestinal microbiota in the pathogenesis of epilepsy, through the so‐called “gut–brain axis,” has yet to be demonstrated. In this study, we evaluated the direct impact of microbiota transplanted from epileptic animals to healthy recipient animals, to clarify whether the microbiota from animals with epilepsy can affect the excitability of the recipients’ brain by lowering seizure thresholds. Our results provide the first evidence that mice who received microbiota from epileptic animals are more prone to develop status epilepticus, compared to recipients of “healthy” microbiota, after a subclinical dose of pilocarpine, indicating a higher susceptibility to seizures. The lower thresholds for seizure activity found in this study support the hypothesis that the microbiota, through the gut–brain axis, is able to affect neuronal excitability in the brain.

18 July 2006 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
AMAdéla Mátéffyová
Adéla Mátéffyová
JOJakub Otáhal
Jakub Otáhal
GTGrygoriy Tsenov
Grygoriy Tsenov
PMPavel Mareš
Pavel Mareš
Hana KubovaHana Kubova
Hana Kubova

1 September 2007 in Epilepsia
Verified
Journal Article
Open access
PDF file
GTGrygoriy Tsenov
Grygoriy Tsenov
AMAdéla Mátéffyová
Adéla Mátéffyová
PMPavel Mareš
Pavel Mareš
JOJakub Otáhal
Jakub Otáhal
Hana KubovaHana Kubova
Hana Kubova
The goal of this study was to develop a new model of ischemia-induced seizures in immature rats using injection of vasoconstrictor Endothelin-1 (ET-1) into the brain. ET-1 (10, 20, or 40 pmol) was infused into the left dorsal hippocampus of freely moving Wistar rats 12 (P12) and 25 (P25) days old. Animals were then video/EEG-monitored for 100 min and monitoring was repeated 22 h later. Parameters of electrographic seizures (frequency and mean duration) as well as pattern of their behavioral correlates were evaluated. The pattern of behavioral seizures was used to develop model-specific scoring system. Cresyl violet and Fluoro Jade-B-staining were used to evaluate brain damage. Extension of the lesion was correlated with seizure severity. After ET-1-injection, seizures occurred in 83-100% animals of all age-and-dose groups and persisted for 24 h except P12 rats with 10 pmol. There were no differences in average seizure duration (18-40 s) or seizure frequency (3-7 seizures/100 min) among individual dose-groups. Between the 1st and 2nd observation period, total seizure duration decreased in 71% of P12 and 47% of P25 rats. Electrographic seizure activity was most frequently accompanied by clonus, incidence of more severe convulsions (barrel rolling or generalized clonic seizures) increased with dose of ET-1. Morphologic examination did not reveal any dose-related difference in damage severity, hippocampal damage was however more extensive in P12 compared to P25 animals. Seizure severity correlated positively with severity of the damage in both age groups. Our study presents focal injection of ET-1 into the brain as a new and practical model of ischemia-induced seizures in immature rats.

1 April 2014 in Neuroscience Letters
Verified
Journal Article
Closed access
LKLenka Kleteckova
Lenka Kleteckova
GTGrygoriy Tsenov
Grygoriy Tsenov
Hana KubovaHana Kubova
Hana Kubova
ASAles Stuchlik
Ales Stuchlik
KVKarel Vales
Karel Vales

1 November 2019 in Cells
Verified
Journal Article
Open access
PDF file
MDMichela Deiana
Michela Deiana
Giovanni MalerbaGiovanni Malerba
Giovanni Malerba
Luca Dalle CarbonareLuca Dalle Carbonare
Luca Dalle Carbonare
SCSAMUELE CHERI
SAMUELE CHERI
CPCristina Patuzzo
Cristina Patuzzo
Maria Teresa ValentiMaria Teresa Valenti
Maria Teresa Valenti
Osteoarthritis (OA) is predominantly characterized by the progressive degradation of articular cartilage, the connective tissue produced by chondrocytes, due to an imbalance between anabolic and catabolic processes. In addition, physical activity (PA) is recognized as an important tool for counteracting OA. To evaluate PA effects on the chondrocyte lineage, we analyzed the expression of SOX9, COL2A1, and COMP in circulating progenitor cells following a half marathon (HM) performance. Therefore, we studied in-depth the involvement of metabolites affecting chondrocyte lineage, and we compared the metabolomic profile associated with PA by analyzing runners’ sera before and after HM performance. Interestingly, this study highlighted that metabolites involved in vitamin B6 salvage, such as pyridoxal 5′-phosphate and pyridoxamine 5′-phosphate, were highly modulated. To evaluate the effects of vitamin B6 in cartilage cells, we treated differentiated mesenchymal stem cells and the SW1353 chondrosarcoma cell line with vitamin B6 in the presence of IL1β, the inflammatory cytokine involved in OA. Our study describes, for the first time, the modulation of the vitamin B6 salvage pathway following PA and suggests a protective role of PA in OA through modulation of this pathway.